* Core Laboratories Inc CLB.N CLB is expected to show a
rise
in quarterly revenue when it reports results on January 31 for
the period ending December 31 2023
* The Houston Texas-based company is expected to report a
0.2% increase in revenue to $127.77 million from $127.57 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.The company's guidance on November 2 2023,
for the period ended December 31, was for revenue between
$125.00 million and $132.00 million.
* LSEG's mean analyst estimate for Core Laboratories Inc is
for
earnings of 19 cents per share. The company's EPS guidance on
November 2 2023, for the period ended December 31, was between
$0.17 and $0.23
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 6
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Core
Laboratories
Inc is $19.50, above its last closing price of $16.82.
The company's guidance on November 2 2023 for the period ended
December 31 was for Earnings before Interest and Taxes between
USD13.8 million and USD17.3 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 0.22 0.22 0.22 Met -0.1
Jun. 30 2023 0.20 0.20 0.21 Beat 5.3
Mar. 31 2023 0.16 0.16 0.19 Beat 20.3
Dec. 31 2022 0.19 0.20 0.20 Met 2.2
Sep. 0.15 0.15 0.18 Beat 20.3
30 2022
Jun. 30 2022 0.12 0.14 0.12 Missed -12
Mar. 31 2022 0.07 0.09 0.08 Missed -11.6
Dec. 31 2021 0.20 0.20 0.20 Met -0.4
This summary was machine generated January 29 at 21:19 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)